Using a 95% sensitivity threshold, the proportions of unnecessary biopsies avoided were 15% for PSA alone, 27% for the Prostate Cancer Prevention Trial risk calculator, 30% for PHI, 30% for the derived multiplex 2-gene model, 17% for the derived multiplex 3-gene model, and 27% for MPS compared with 35% for MPS2 (Table 2; eTable 6 in Supplement 1). This evidence concerns the gene KLK3 and Familial prostate cancer.